{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:41:48Z","timestamp":1785181308565,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.micpath.2019.103912","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T02:33:18Z","timestamp":1575599598000},"page":"103912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis"],"prefix":"10.1016","volume":"139","author":[{"given":"Feng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2019.103912_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.micpath.2019.103912_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatology International"},{"key":"10.1016\/j.micpath.2019.103912_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.saa.2014.01.066","article-title":"Experimental and molecular docking studies on DNA binding interaction of adefovir dipivoxil: advances toward treatment of hepatitis B virus infections","volume":"125","author":"Shahabadi","year":"2014","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.micpath.2019.103912_bib4","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/cid\/ciu702","article-title":"A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B \u201ce\u201d Antigen-Positive Chronic Hepatitis B","volume":"59","author":"Xie","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2019.103912_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jvh.12341","article-title":"Combination therapy of interferon and nucleotide\/nucleoside analogues for chronic hepatitis B","volume":"21","author":"Wong","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.micpath.2019.103912_bib6","first-page":"154","article-title":"Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis","volume":"23","author":"Kim RMA","year":"2015","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.micpath.2019.103912_bib7","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.micpath.2019.103912_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.micpath.2019.103912_bib9","series-title":"Quantifying Heterogeneity in a Meta-Analysis","author":"Thompson JPTHSG","year":"2002"},{"key":"10.1016\/j.micpath.2019.103912_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0011-393X(02)80023-6","article-title":"Efficacy of interferon alfa and lamivudine combination therapy versus interferon alfa monotherapy in Turkish patients with chronic hepatitis B_ A double-blind, randomized, comparative study","volume":"63","author":"Mehmet Cindoruk","year":"2002","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.micpath.2019.103912_bib11","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1086\/375085","article-title":"Comparison of 12-month courses of interferon-a-2b\u2013lamivudine combination therapy and interferon-a-2b monotherapy among patients with untreated chronic hepatitis B","volume":"36","author":"Kendal Yalcin","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2019.103912_bib12","series-title":"Peginterferon Alfa-2a, Lamivudine,and the Combination for HBeAg-Positive Chronic Hepatitis B","author":"George","year":"2005"},{"key":"10.1016\/j.micpath.2019.103912_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"The Lancet"},{"key":"10.1016\/j.micpath.2019.103912_bib14","first-page":"71","article-title":"Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B","volume":"25","author":"Celal Ayaz","year":"2006","journal-title":"Indian J. Gastroenterol."},{"key":"10.1016\/j.micpath.2019.103912_bib15","first-page":"680","article-title":"Improved efficacy by individualized combination therapy with peg IFN-\u03b1 2a and ADV in HBeAg positive chronic hepatitis B patients","volume":"59","author":"Ya-Dong Wang","year":"2012","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.micpath.2019.103912_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11596-014-1312-2","article-title":"Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study","volume":"34","author":"Liu","year":"2014","journal-title":"J. Huazhong Univ. Sci. Technol. - Med. Sci."},{"key":"10.1016\/j.micpath.2019.103912_bib17","doi-asserted-by":"crossref","first-page":"e4471","DOI":"10.1097\/MD.0000000000004471","article-title":"CONSORT: effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positive patients: a prospective, randomized study","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.micpath.2019.103912_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11596-017-1771-3","article-title":"Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B","volume":"37","author":"Li","year":"2017","journal-title":"J. Huazhong Univ. Sci. Technol. - Med. Sci."},{"key":"10.1016\/j.micpath.2019.103912_bib19","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4103\/0366-6999.235880","article-title":"Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen Positive Hepatitis B Patients: a Randomized,Multicenter, Phase IIIb OpenLabel Study (POTENT Study)","volume":"131","author":"Dae Won Jun","year":"2018","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.micpath.2019.103912_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alfa-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.micpath.2019.103912_bib21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.20128","article-title":"Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B","volume":"39","author":"van Zonneveld","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.micpath.2019.103912_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2893.2002.00383.x","article-title":"Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA","volume":"9","author":"Morrissey","year":"2002","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.micpath.2019.103912_bib23","first-page":"276","article-title":"[Hepatitis B virus infection: control or cure?]","volume":"68","author":"Bourliere","year":"2018","journal-title":"La Revue du praticien"},{"key":"10.1016\/j.micpath.2019.103912_bib24","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.micpath.2019.103912_bib25","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.micpath.2019.103912_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1128\/AAC.00467-07","article-title":"Hepatitis B Virus e Antigen Loss during Adefovir Dipivoxil Therapy Is Associated with Enhanced Virus-Specific CD4+ T-Cell Reactivity","volume":"52","author":"Cooksley","year":"2007","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401019312008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401019312008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:27:57Z","timestamp":1760110077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401019312008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":26,"alternative-id":["S0882401019312008"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2019.103912","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2019.103912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103912"}}